Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

All was not positive on the GLP-1 drug front, though. On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager (PBM) unit Caremark would make rival weight ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with Purdue University over the next eight years. The boosted pact with the ...

Big move on Thursday as investors in Eli Lilly and Company (LLY) endured an almost 12% downside as investors consider the aftermath of the CVS formulary decision changes that impacted the ...

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong pricing power, which enables the firm to generate ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

Despite last week's investor jitters, Eli Lilly is far from losing its strong ... according to a pre-recorded demo. Health-care organizations can implement Zo without any upfront fees, long ...

President Donald Trump signed a new executive order aimed at boosting domestic drug manufacturing. The executive order comes ahead of the Trump administration's planned tariffs on pharmaceuticals ...

Amyotrophic lateral sclerosis has been a tough area for drug research, but Eli Lilly has been spreading its bets in this neurodegenerative disease by striking deals with other companies.